What is it about?
Each of us has unique DNA sequences. Identifying which of these sequences underlie the risk for developing kidney disease has become a major area of study. This paper reviews the strengths and weaknesses of using genes to guide drug discovery in diabetic kidney disease.
Featured Image
Photo by Lewis J Goetz on Unsplash
Why is it important?
Diabetic kidney disease is main cause of kidney failure requiring dialysis and the major risk for death in diabetic patients however there are only two known treatments that only partially reduce this risk. The new access to genetic sequence information offers hope for identifying new treatments.
Perspectives
Genetic studies have provided novel drug targets for atherosclerosis and cancer, but have yet to yield new therapies for diabetic kidney disease. We need to marry deeper understanding of kidney disease mechanisms with emerging genetic information to bridge this gap.
Matthew Breyer
Janssen pharmaceutical
Read the Original
This page is a summary of: The Use of Genomics to Drive Kidney Disease Drug Discovery and Development, Clinical Journal of the American Society of Nephrology, March 2020, American Society of Nephrology,
DOI: 10.2215/cjn.11070919.
You can read the full text:
Resources
Contributors
The following have contributed to this page
